These results indicated that targeting CRC biomarkerspromoted binding and active uptake of nanoparticles by the tumor cells,resulting in enhanced systemic targeting of CEA-FSNs compared to passiveaccumulation of PEG-FSNs. The gene discussed is CEACAM5; the disease is colorectal carcinoma.